With regard to the breast cancer phenotype, 111 (52.9%) trials enrolled patients with various phenotypes, 40 (19.0%) were dedicated to hormone-receptor-positive disease alone, 33 (15.7%) to HER2-positive disease (regardless of hormone receptors), and seven trials (3.3%) to triple-negative breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.